Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: J Allergy Clin Immunol. 2019 Sep 4;144(5):1320–1326.e1. doi: 10.1016/j.jaci.2019.07.030

FIG 2.

FIG 2.

Desensitization thresholds during DBPCFC post-SLIT therapy: Maximum cumulative tolerated dose achieved for each subject during post-SLIT therapy 5000 mg DBPCFC.